Business
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer.
About this update from Oncology Pharma Inc.
[{"type":"text","content":"SAN FRANCISCO, CA / ACCESSWIRE / April 13, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma ("The Company") is pleased to announce that it has completed the initial feasibility phase of its licensed dactinomycin nanoemulsion. The successful completion of the feasibility stage marks the initial planned milestone for this development project. Data is currently under evaluation and discussions regarding future development and milestones are underway.The goal of this initial feasibility phase was to demonstrate the capability of producing viable drug formulations with desirable delivery system characteristics. These include the encapsulation of the active pharmaceutical ingredient (dactinomycin) by the nanoemulsion, a controlled release over time, desirable storage stability, and appropriate particle size and surface charge.While many nanoemulsion formulations are limited by very short storage stability, some with shelf-lives of mere hours after formulating the dosing solution. Early feasibility data collected from the licensed proprietary nanoemulsion formulation being developed as part of this project has demonstrated multiple weeks of stability, with anticipated stability of several months. In addition, initial analytical method validation work was conducted at an independent contract laboratory to develop the capability of assessing drug concentration in samples, which will be critical for successful completion of future preclinical studies.From the various formulations created and assessed during this feasibility phase, two likely drug formulations have been identified that have the desired characteristics to enable further development.The nanoemulsion delivery system is intended to increase the overall safety of dactinomycin, a potent cancer drug that has been previously cleared to treat cancer, including pediatric cancer, but has limited utility due to its high toxicity and narrow safety margin ("therapeutic window"). By encapsulating the dactinomycin in a nanoemulsion carrier, the drug is released over time and thus improves its safety profile (much like coated aspirin is designed to prevent stomach upset without interfering with its pain-relieving properties).From the various formulations created and assessed during this feasibility phase, two likely drug formulations have been identified that...